Navigation Links
RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program
Date:1/24/2011

tive to private partners in order to get a treatment to patients, TRND advances a potential compound through the drug development process to the point where it can be tested in people. TRND provides all aspects of preclinical development needed to turn promising compounds into potential medicines ready for clinical evaluation.

"This partnership is another validation of our development philosophy and the success we've achieved with other products," said Scott Tarrant, Chief Business Officer at RRD International. "Work on these rare diseases will demonstrate the flexibility of our asset-centric model and how RRD efficiently drives development while mitigating cost and risk factors which, historically, have served as barriers to new therapies for rare and neglected diseases."

The TRND program will collaborate with academic organizations, foundations, biotechs, and pharmaceutical companies to develop clinical candidate drugs that can be adopted by biopharma for completion of clinical development and FDA approval.  In addition to individual drug development projects, TRND is developing technologies and paradigms to reduce the very high risks and cost of drug development. The ultimate goal is to "de-risk" rare and neglected disease drug development by accomplishing lead optimization through an FDA Investigational New Drug (IND) application and, when needed, proof-of-concept in human studies.

About RRD International

Founded in 2002, RRD is a strategy-driven product development company.  The Company's development model enables rapid proof-of-concept for biotech and pharmaceutical clients to accelerate value inflection points; reduce costs; and mitigate development as well as execution risk.  RRD offers two distinct types of client engagements:  TacDev® and DevCo®.  The TacDev® model adds development bandwidth and expertise for defined products in companies with minimal infras
'/>"/>

SOURCE RRD International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. CSA Medical Selected to Present at Mid-Atlantic Bio Conference
3. PMC BioTec Selected as a GoingGreen Silicon Valley 100 Winner
4. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
5. Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility
6. Ion Torrent Selected as World Economic Forum Technology Pioneer
7. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
8. Genedata Phylosopher Selected for ERA-NET sncRNA Project
9. NeoStem Selected to Present at American Society for Apheresis
10. DNA Genoteks Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project
11. OrthoAccel Technologies, Inc. Selected to Pitch at the 2010 WBTshowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... Germany, Sept. 1 ,Boston Scientific Corporation (NYSE: ... its landmark SYNTAX trial comparing percutaneous coronary ... Stent,System to contemporary coronary artery bypass graft ... significant differences,between PCI and CABG in rates ...
... to realize the electrical units of voltage, resistance ... nano-circuits are nowadays used. Important prerequisites are extremely ... the crystal without collision with residual impurities. To ... PTB has set up a new molecular beam ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced that Michael ... present at BioCentury,s,Newsmakers in the Biotech Industry Conference in ... ET., To access the live webcast or the ... to the Investors page, and click on Events.,Please connect ...
Cached Biology Technology:Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 2Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 4Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 5'Racetrack' for fast electrons in semiconductor structures 2Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008 2
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... EUGENE, Ore.(Aug. 20, 2007)Nitric acid is a notoriously strong and ... our atmosphere. However, a team of researchers have found that ... top of a water surface. The discovery of the ... the surface of water requires us to re-evaluate how we ...
... of G&D, Drs. Maria Divina Deato and Robert Tjian ... alternative transcriptional core promoter complex directs cell-type specific differentiation ... of transcriptional control of terminal cell differentiation, and will ... date at www.genesdev.org . For nearly 30 ...
... after prior full-dose conventional radiation therapy respond to Boron ... a Phase I/II study at the Helsinki University Hospital, ... Heikki Joensuu, University of Helsinki, considers the results ... field for BNCT, since thus far BNCT has been ...
Cached Biology News:University of Oregon researcher finds that on water's surface, nitric acid is not so tough 2A new radiation therapy treatment developed for head and neck cancer patients 2
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
Biology Products: